Performance evaluation of BD FACSPresto™ point of care CD4 analyzer to enumerate CD4 counts for monitoring HIV infected individuals in Nigeria
Open Access
- 25 May 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (5) , e0178037
Abstract
Despite the upsurge in support and intervention of donor agencies in HIV care and treatment programing in Sub-Sahara African, antiretroviral (ART) programs are still confronted with access and coverage challenges which influence enrolment of new patients. This study investigated the validity of point of care BD FACSPresto™ CD4 analyzer for CD4+ cell count, overall agreement, correlation, sensitivity, and specificity in comparison to a reference standard flow cytometry method. We also assessed the feasibility of use among non-laboratorians. Blood samples from 300 HIV infected individuals were analyzed for CD4+ T cell and CD4%, using finger prick capillary sample from 150 PMTCT clients and 150 ART clients at Murtala Mohammed Specialist Hospital, Kano, Nigeria. Their venous samples were compared on a flow cytometry reference method using BD FACSCount CD4+ count system. The accuracy of the BD FACSPresto machine in comparison to BD FACSCount was evaluated. Statistical analysis was carried out using STATA (version 12). Bland-Altman method and correlation analysis were used to analyze agreement between both measurements. In addition, sensitivity and specificity of both measurements were determined. Statistical significance was set at p-value <0.05. The mean bias and limit of agreement for CD4+ count between BD FACSPresto and BD FACS count machine were 7.49 (95% CI: 2.44 to 12.54) and -8.14 to 96.39 respectively. Further analysis revealed close agreement between BD FACSPresto and BD FACSCount with no significant difference between the two methods (p = .0.95). Using a threshold of 500 cells/μL, sensitivity and specificity of BD FACSPresto were 95.1% and 97.1% respectively, compared to BD FACSCount. There was no statistically significant difference in the misclassification between BD FACSPresto and BD FACSCount results (p = 0.23). Furthermore, sensitivity and specificity were similar when BD FACSPresto machine was operated by a nurse or laboratory scientist, there was no substantial difference in testing variability observed between laboratory and non-laboratory operators using the BD FACSPresto analyzer. Overall, BD FACSPresto Point of Care CD4+ count finger stick capillary blood results is a reliable method in comparison to venous sample cytometry method and no significant difference variability observed between laboratory personnel and non-laboratory operators. The BD FACSPresto is simple, more robust and easy to use equipment without significant variability in reliability by non-laboratory health care workers hence will be a valuable instrument in increasing access and coverage of CD4 estimations in developing countries. The introduction of the BD FACSPresto POC analyzer has a high potential in reducing patients waiting time and improving the overall quality of ART service and clients’ satisfaction especially in rural settings.Keywords
Funding Information
- BD Biosciences (US)
This publication has 17 references indexed in Scilit:
- Clinical Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in KenyaPLOS ONE, 2016
- Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges: Table 1.Clinical Infectious Diseases, 2016
- The Reliability of Point-of-Care CD4 Testing in Identifying HIV-Infected Pregnant Women Eligible for Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Evaluation of Portable Point-of-Care CD4 Counter with High Sensitivity for Detecting Patients Eligible for Antiretroviral TherapyPLOS ONE, 2012
- Utility of the point of care CD4 analyzer, PIMA, to enumerate CD4 counts in the field settings in IndiaAIDS Research and Therapy, 2012
- Emerging technologies for point-of-care CD4 T-lymphocyte countingTrends in Biotechnology, 2012
- Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort studyThe Lancet, 2011
- Advances in developing HIV-1 viral load assays for resource-limited settingsBiotechnology Advances, 2010
- Enhancing the performance of a point-of-care CD4+ T-cell counting microchip through monocyte depletion for HIV/AIDS diagnosticsLab on a Chip, 2009
- HIV Viral Load Monitoring in Resource‐Limited Regions: Optional or Necessary?Clinical Infectious Diseases, 2007